Policy | September 26, 2023
India to launch National Policy on Research and Development and Innovation in Pharma-MedTech
Also to be launched Scheme for promotion of Research and Innovation in Pharma MedTech Sector (PRIP)
Also to be launched Scheme for promotion of Research and Innovation in Pharma MedTech Sector (PRIP)
To enable company to be future-ready by tapping potential in CDMO space
Academia-industry partnership to promote indigenous technology commercialization in biotech sector
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Subscribe To Our Newsletter & Stay Updated
